Supratentorial grade II astrocytoma: Biological features and clinical course

Lancet Neurology

Volumn 2, Issue 7, 2003, Pages 395-403

  Wessels, Peter H ^a   Weber, Wim E J ^a   Raven, Guy ^a   Ramaekers, Frans C S ^b   Hopman, Anton H N ^b   Twijnstra, Albert ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ASTROCYTOMA; BIOPSY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; GENOTYPE; HEADACHE; HISTOLOGY; HUMAN; IN SITU HYBRIDIZATION; INTRACRANIAL HYPERTENSION; KARYOTYPING; MENTAL DISEASE; MUTATIONAL ANALYSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPILLEDEMA; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION DOSE; REVIEW; SEIZURE; VOMITING;

EID: 0037711908     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00434-4     Document Type: Review

References (121)

1. van der Sanden G.A.C., Schouten L.J., van Dijck J.A.A.M., van Andel J.P., Coebergh J.W.W. Incidence of primary central nervous system cancers in South and East Netherlands in 1989-1994. Neuroepidemiology. 17:1998;247-257.
2. Shaw E.G., Daumas-Duport C., Scheithauer B.W., et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg. 70:1989;853-861.
3. Louis D.N., von Deimling A. Hereditary tumor syndromes of the nervous system: overview and rare syndromes. Brain Pathol. 5:1995;145-151.
4. Salvati M., Artico M., Caruso R., Rocchi G., Orlando E.R., Nucci F. A report on radiation-induced gliomas. Cancer. 67:1991;392-397.
5. Preston-Martin S. Epidemiology of primary CNS neoplasms. Neurol Clin. 14:1996;273-290.
6. Inskip P.D., Tarone R.E., Hatch E.E., et al. Cellular-telephone use and brain tumors. N Engl J Med. 344:2001;79-86.
7. Fleury A., Menegoz F., Grosclaude P., et al. Descriptive epidemiology of cerebral gliomas in France. Cancer. 79:1997;1195-1202.
8. Lote K., Egeland T., Hager B., et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol. 15:1997;3129-3140.
9. Kreth F.W., Faist M., Rossner R., Volk B., Ostertag C.B. Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas: a new pattern of prognostic factors. Cancer. 79:1997;370-379.
10. Leighton C., Fisher B., Bauman G., et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 15:1997;1294-1301.
11. Smith D.F., Hutton J.L., Sandemann D., et al. The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management. J Neurol Neurosurg Psychiatry. 54:1991;915-920.
12. Laws E.R., Taylor W.F., Clifton M.B., Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. 61:1984;665-673.
13. Vertosick F.T., Selker R.G., Arena V.C. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery. 28:1991;496-501.
14. Philippon J.H., Clemenceau S.H., Fauchon F.H., Foncin J.F. Supratentorial low-grade astrocytomas in adults. Neurosurgery. 32:1993;554-559.
15. Galanis E., Buckner J.C., Novotny P., et al. Efficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas. J Neurosurg. 93:2000;201-207.
16. Kelly P.J., Daumas-Duport C., Kispert D.B., Kall B.A., Scheithauer B.W., Illig J.J. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 66:1987;865-874.
17. Silverman C., Marks J.E. Prognostic significance of contrast enhancement in low-grade astrocytomas of the adult cerebrum. Radiology. 139:1981;211-213.
18. Kondziolka D., Lunsford L.D., Martinez A.J. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg. 79:1993;533-536.
19. Barker F.G., Chang S.M., Huhn S.L., et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer. 80:1997;936-941.
20. Scott J.N., Brasher P.M., Sevick R.J., Rewcastle N.B., Forsyth P.A. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 59:2002;947-949.
21. De Witte O., Levivier M., Violon P., et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery. 39:1996;470-476.
22. Nuutinen J., Sonninen P., Lehikoinen P., et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys. 48:2000;43-52.
23. Ogawa T., Kanno I., Shishido F., et al. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol. 32:1991;197-202.
24. Nelson S.J., Vigneron D.B., Dillon W.P. Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed. 12:1999;123-138.
25. Mason W., MacDonald D. Low-grade gliomas. Vecht C.J. Neuro-oncology: part II. 1997;33-60 Elsevier Science, Amsterdam.
26. Whitton A.C., Bloom H.J. Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys. 18:1990;783-786.
27. North C.A., North R.B., Epstein J.A., Piantadosi S., Wharam M.D. Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer. 66:1990;6-14.
28. McCormack B.M., Miller D.C., Budzilovich G.N., Voorhees G.J., Ransohoff J. Treatment and survival of low-grade astrocytoma in adults - 1977-1988. Neurosurgery. 31:1992;636-642.
29. Shibamoto Y., Kitakabu Y., Takahashi M., et al. Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer. 72:1993;190-195.
30. Rajan B., Pickuth D., Ashley S., et al. The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys. 28:1994;405-413.
31. Firsching R., Tieben R., Schroder R., Stutzer R. Long-term prognosis of low grade astrocytoma. Zentralbl Neurochir. 55:1994;10-15.
32. Berger M.S., Deliganis A.V., Dobbins J., Keles G.E. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 74:1994;1784-1791.
33. Janny P., Cure H., Mohr M., et al. Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer. 73:1994;1937-1945.
34. Nicolato A., Gerosa M.A., Fina P., Iuzzolino P., Giorgiutti F., Bricolo A. Prognostic factors in low-grade supratentorial astrocytomas: a uni- multivariate statistical analysis in 76 surgically treated adult patients. Surg Neurol. 44:1995;208-221.
35. Touboul E., Schlienger M., Buffat L., et al. Radiation therapy with or without surgery in the management of low- grade brain astrocytomas: a retrospective study of 120 patients. Bull Cancer Radiother. 82:1995;388-395.
36. Piepmeier J.M. Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. J Neurosurg. 67:1987;177-181.
37. Bahary J.P., Villemure J.G., Choi S., et al. Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era. J Neurooncol. 27:1996;173-177.
38. Schuurman P.R., Troost D., Verbeeten B., Bosch D.A. 5-year survival and clinical prognostic factors in progressive supratentorial diffuse "low-grade" astrocytoma: a retrospective analysis of 46 cases. Acta Neurochir. 139:1997;2-7.
39. van Veelen M.L.C., Avezaat C.J.J., Kros J.M., van Putten W., Vecht C.J. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 64:1998;581-587.
40. Peraud A., Ansari H., Bise K., Reulen H.J. Clinical outcome of supratentorial astrocytoma WHO grade II. Acta Neurochir. 140:1998;1213-1222.
41. Bauman G., Lote K., Larson D., et al. Pretreatment factors predict overall survival for patients with low- grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 45:1999;923-929.
42. Nakamura M., Konishi N., Tsunoda S., et al. Analysis of prognostic and survival factors related to treatment of low- grade astrocytomas in adults. Oncology. 58:2000;108-116.
43. Arienti V.M., Botturi A., Boiardi A., et al. Adult brain low-grade astrocytomas: survival after surgery and radiotherapy. Neurol Sci. 22:2001;233-238.
44. Eyre H.J., Crowley J.J., Townsend J.J., et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg. 78:1993;909-914.
45. Karim A.B.M.F., Maat B., Hatlevoll R., et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 36:1996;549-556.
46. Karim A.B.M.F., Afra D., Cornu P., et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 52:2002;316-324.
47. Shaw E., Arusell R., Scheithauer B., et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 20:2002;2267-2276.
48. Pignatti F., van den Bent M., Curran D., et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 20:2002;2076-2084.
49. Piepmeier J.M., Fried I., Makuch R. Low-grade astrocytomas may arise from different astrocyte lineages. Neurosurgery. 33:1993;627-632.
50. Muller W., Afra D., Schroder R. Supratentorial recurrences of gliomas. Morphological studies in relation to time intervals with astrocytomas. Acta Neurochir. 37:1977;75-91.
51. Fried I., Kim J.H., Spencer D.D. Limbic and neocortical gliomas associated with intractable seizures: a distinct clinicopathological group. Neurosurgery. 34:1994;815-823.
52. Vecht C.J. Effect of age on treatment decisions in low-grade glioma. J Neurol Neurosurg Psychiatry. 56:1993;1259-1264.
53. Keles G.E., Lamborn K.R., Berger M.S. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 95:2001;735-745.
54. Klein M., Heimans J.J., Aaronson N.K., et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 360:2002;1361-1368.
55. Quinn J.A., Reardon D.A., Friedman A.H., et al. Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma. J Clin Oncol. 21:2003;646-651.
56. Stupp R., Gander M., Leyvraz S., Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2:2001;552-560.
57. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 90:1998;1473-1479.
58. Recht L.D., Lew R., Smith T.W. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol. 31:1992;431-436.
59. Reijneveld J.C., Sitskoorn M.M., Klein M., Nuyen J., Taphoorn M.J.B. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology. 56:2001;618-623.
60. Daumas-Duport C., Scheithauer B., O'Fallon J., Kelly P. Grading of astrocytomas: a simple and reproducible method. Cancer. 62:1988;2152-2165.
61. Kleihues P., Cavenee W.K. Pathology and genetics of tumors of the nervous system. 2nd edn:2000;International agency for research on cancer, Lyon.
62. Krouwer H.G., Davis R.L., Silver P., Prados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg. 74:1991;399-406.
63. McLendon R.E., Enerline D.S., Tien R.T., Thorstad W.L., Bruner J.M. Tumors of central neuroepithelial origin. Bigner D.D., McLendon R.E., Bruner J.M. Russell & Rubinstein's pathology of tumors of the nervous system. 6th edn:1998;307-573 Arnold, London.
64. Prayson R.A., Estes M.L. Protoplasmic astrocytoma: a clinicopathologic study of 16 tumors. Am J Clin Pathol. 103:1995;705-709.
65. Kim T.S., Halliday A.L., Hedley-Whyte E.T., Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg. 74:1991;27-37.
66. Kleihues P., Burger P.C., Scheithauer B.W. The new WHO classification of brain tumours. Brain Pathol. 3:1993;255-268.
67. Giannini C., Scheithauer B.W., Burger P.C., et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol. 58:1999;46-53.
68. Paulus W., Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer. 64:1989;442-447.
69. Chandrasoma P.T., Smith M.M., Apuzzo M.L. Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimen. Neurosurgery. 24:1989;160-165.
70. Feiden W., Steude U., Bise K., Gundisch O. Accuracy of stereotactic brain tumor biopsy: comparison of the histologic findings in biopsy cylinders and resected tumor tissue. Neurosurg Rev. 14:1991;51-56.
71. Daumas-Duport C. Histological grading of gliomas. Curr Opin Neurol Neurosurg. 5:1992;924-931.
72. Cairncross J.G., Macdonald D.R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 23:1988;360-364.
73. Coons S.W., Johnson P.C., Scheithauer B.W., Yates A.J., Pearl D.K. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 79:1997;1381-1393.
74. Bruner J.M. Neuropathology of malignant gliomas. Semin Oncol. 21:1994;126-138.
75. McKeever P.E., Strawderman M.S., Yamini B., Mikhail A.A., Blaivas M. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol. 57:1998;931-936.
76. Schiffer D., Cavalla P., Chio A., Richiardi P., Giordana M.T. Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol. 34:1997;31-35.
77. Sallinen S.L., Sallinen P., Haapasalo H., et al. Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas. Am J Pathol. 151:1997;1799-1807.
78. Wessels P.H., Twijnstra A., Kessels A.G.H., et al. Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer. 33:2002;279-284.
79. Ito S., Chandler K., Prados M., et al. Proliferative potential and prognostic evaluation of low-grade astrocytomas. J Neurooncol. 19:1994;1-9.
80. Hoshino T., Ahn D., Prados M.D., Lamborn K., Wilson C.B. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int J Cancer. 53:1993;550-555.
81. Onda K., Davis R.L., Shibuya M., Wilson C.B., Hoshino T. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer. 74:1994;1921-1926.
82. Louis D.N., Edgerton S., Thor A.D., Hedley-Whyte E.T. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol (Berl). 81:1991;675-679.
83. Sallinen P.K., Haapasalo H.K., Visakorpi T., et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol. 174:1994;275-282.
84. Rey J.A., Bello M.J., de Campos J.M., Kusak M.E., Ramos C., Benitez J. Chromosomal patterns in human malignant astrocytomas. Cancer Genet Cytogenet. 29:1987;201-221.
85. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
86. von Deimling A., Fimmers R., Schmidt M.C., et al. Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol. 59:2000;544-558.
87. Arnoldus E.P., Noordermeer I.A., Peters A.C., et al. Interphase cytogenetics of brain tumors. Genes Chromosomes Cancer. 3:1991;101-107.
88. Schlegel J., Scherthan H., Arens N., Stumm G., Kiessling M. Detection of complex genetic alterations in human glioblastoma multiforme using comparative genomic hybridization. J Neuropathol Exp Neurol. 55:1996;81-87.
89. Huang H., Colella S., Kurrer M., Yonekawa Y., Kleihues P., Ohgaki H. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res. 60:2000;6868-6874.
90. Hopman A.H.N., Ramaekers F.C.S. Processing and staining of cell and tissue material for interphase cytogenetics. Robinson P. Current protocols in cytometry. 1998;John Wiley & Sons, Inc, New York. Chapter 8.5.1-8.5.2.
91. Cremer T., Lichter P., Borden J., Ward D.C., Manuelidis L. Detection of chromosome aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome-specific library probes. Hum Genet. 80:1988;235-246.
92. Jeuken J.W.M., Sprenger S.H.E., Wesseling P. Comparative genomic hybridization: practical guidelines. Diagn Mol Pathol. 11:2002;193-203.
93. Darling J.L., Warr T.J., Ashmore S.M., Luxsuwong M., Revesz T. Non-isotopic molecular cytogenetics in neuro-oncology. Neuropathol Appl Neurobiol. 23:1997;441-456.
94. Collins V.P. Progression as exemplified by human astrocytic tumors. Semin Cancer Biol. 9:1999;267-276.
95. Zhu Y., Parada L.F. The molecular and genetic basis of neurological tumours. Nat Rev Cancer. 2:2002;616-626.
96. Kleihues P., Ohgaki H. Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol. 7:1997;1131-1136.
97. Fuller G.N., Bigner S.H. Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat Res. 276:1992;299-306.
98. James C.D., Carlbom E., Dumanski J.P., et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 48:1988;5546-5551.
99. von Deimling A., Eibl R.H., Ohgaki H., et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res. 52:1992;2987-2990.
100. Guha A., Feldkamp M.M., Lau N., Boss G., Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 15:1997;2755-2765.
101. Hermanson M., Funa K., Koopmann J., et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res. 56:1996;164-171.
102. Wernicke C., Thiel G., Lozanova T., Vogel S., Witkowski R. Numerical aberrations of chromosomes 1, 2, and 7 in astrocytomas studied by interphase cytogenetics. Genes Chromosomes Cancer. 19:1997;6-13.
103. Perry A., Tonk V., McIntire D.D., White C.L. Interphase cytogenetic (in situ hybridization) analysis of astrocytomas using archival, formalin-fixed, paraffin-embedded tissue and nonfluorescent light microscopy. Am J Clin Pathol. 108:1997;166-174.
104. Nishizaki T., Ozaki S., Harada K., et al. Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosomes Cancer. 21:1998;340-346.
105. Hirose Y., Aldape K.D., Chang S., Lamborn K., Berger M.S., Feuerstein B.G. Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet Cytogenet. 142:2003;1-7.
106. Hurtt M.R., Moossy J., Donovan-Peluso M., Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol. 51:1992;84-90.
107. Oskam N.T., Bijleveld E.H., Hulsebos T.J. A region of common deletion in 22q13.3 in human glioma associated with astrocytoma progression. Int J Cancer. 85:2000;336-339.
108. Ichimura K., Schmidt E.E., Miyakawa A., Goike H.M., Collins V.P. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer. 22:1998;9-15.
109. Olopade O.I., Jenkins R.B., Ransom D.T., et al. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res. 52:1992;2523-2529.
110. Moulton T., Samara G., Chung W.Y., et al. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol. 146:1995;613-619.
111. Nakamura M., Yang F., Fujisawa H., Yonekawa Y., Kleihues P., Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol. 59:2000;539-543.
112. Fujisawa H., Kurrer M., Reis R.M., Yonekawa Y., Kleihues P., Ohgaki H. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol. 155:1999;387-394.
113. Mollenhauer J., Wiemann S., Scheurlen W., et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet. 17:1997;32-39.
114. Chozick B.S., Pezzullo J.C., Epstein M.H., Finch P.W. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery. 35:1994;831-837.
115. Kraus J.A., Bolln C., Wolf H.K., et al. TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer. 10:1994;143-149.
116. Peraud A., Kreth F.W., Wiestler O.D., Kleihues P., Reulen H.J. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res. 8:2002;1117-1124.
117. Wessels P.H., Hopman A.H.N., Ummelen M.I.J., Krijne-Kubat B., Ramaekers F.C.S., Twijnstra A. Differentiation between reactive gliosis and diffuse astrocytoma by in situ hybridization. Neurology. 56:2001;1224-1227.
118. Watanabe T., Nakamura M., Kros J.M., et al. Phenotype versus genotype correlation in oligodendrogliomas and low- grade diffuse astrocytomas. Acta Neuropathol (Berl). 103:2002;267-275.
119. Jeuken J.W.M., Sprenger S.H.E., Wesseling P., et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol. 58:1999;606-612.
120. Fuller G.N., Hess K.R., Rhee C.H., et al. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 12:2002;108-116.
121. Wessels PH, Hopman AHN, Kubat B, et al. Proliferation and aneusomy predict survival of young patients with astrocytoma grade II. Br J Cancer (in press).